<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105230</url>
  </required_header>
  <id_info>
    <org_study_id>sPD1 in RA</org_study_id>
    <nct_id>NCT05105230</nct_id>
  </id_info>
  <brief_title>Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease</brief_title>
  <official_title>Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Evaluate the levels of serum (sPD1) in RA patients with ILD and those without.&#xD;
&#xD;
        2. Detect subclinical RA-ILD for early diagnosis and management of this devastating&#xD;
           manifestation of RA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis is a chronic autoimmune disease that is characterized by a systemic&#xD;
      inflammatory state that affects joints and other organs .&#xD;
&#xD;
      There are many types of RA-related pulmonary diseases. RA-related pulmonary diseases include&#xD;
      airway disease such as bronchiolitis. There are interstitial lung diseases that include&#xD;
      non-specific interstitial pneumonitis and usual interstitial pneumonia .&#xD;
&#xD;
      The pathogenesis of RA is multifactorial with contributions from genetic and environmental&#xD;
      factors. (CD4+) T-cells is responsible for pro-inflammatory cytokines production and&#xD;
      subsequent joint destruction .&#xD;
&#xD;
      The aetiology of RA-ILD may be related to smoking and other factors that activate&#xD;
      autoimmunity and the attack of post-transcriptionally modified self-proteins, such as&#xD;
      citrullinated peptides. Citrullinated peptide can be produced in the lungs of some patients,&#xD;
      causing a pulmonary fibrosis .&#xD;
&#xD;
      Major subtypes of RA-ILD are defined by their histopathological or (HRCT) patterns&#xD;
&#xD;
      . Programmed death-1 belongs to CD28/B7 family and is expressed on the surface of activated T&#xD;
      cells, B cells, NK cells, dendritic cells and Treg cells. sPD-1 is the soluble form of PD-1&#xD;
      that is obtained by phosphoric acid hydrolysis of membrane type PD-1 .&#xD;
&#xD;
      Programmed death-1 and its ligands are important negative regulators of the immune system. .&#xD;
&#xD;
      In RA, Persistent synovial T cell activation and inflammation may be reasoned to positive&#xD;
      regulators overexpression, aberrant expression of negative regulators or functional&#xD;
      antagonism of these molecules by soluble factors .&#xD;
&#xD;
      sPD-1 inhibits the PD-1/PD-L signalling pathway by interacting with PD-Ls and promotes the T&#xD;
      cell activation .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measure the levels of serum (sPD1)by ELISA in RA patients</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluate the levels of serum (sPD1) in RA patients and its correlation with ILD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>early diagnosis of ILD in patients with RA</measure>
    <time_frame>baseline</time_frame>
    <description>Detect subclinical RA-ILD for early diagnosis and management of this devastating manifestation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>soluble programmed death 1biomarker</intervention_name>
    <description>soluble programmed death 1biomarker</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Adult RA Patients&#xD;
&#xD;
          2. Adult RA patients with ILD&#xD;
&#xD;
          3. Adult healthy control&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult RA Patients who fulfilled the 2010 ACR/European league against rheumatism&#xD;
             (EULAR) criteria for the classification of RA (7).&#xD;
&#xD;
          -  Adult RA patients with ILD (Nonspecific idiopathic interstitial pneumonia more than 16&#xD;
             years old).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other autoimmune diseases (systemic lupus erythematosus, polyarteritis&#xD;
             nodosa sarcoidosis, dermatomyositis, scleroderma, spondylarthritis and inflammatory&#xD;
             bowel disease).&#xD;
&#xD;
          -  RA patients with lung affection other than ILD&#xD;
&#xD;
          -  Patients with malignant tumors&#xD;
&#xD;
          -  Patients with active infection&#xD;
&#xD;
          -  Patients with severe heart, lung, and kidney dysfunction&#xD;
&#xD;
          -  Patients with tuberculosis, pulmonary infection, chronic obstructive pulmonary&#xD;
             disease, bronchiectasis, lung tumor, and pneumoconiosis disease.&#xD;
&#xD;
          -  Uses of drugs (other than RA medication) known to cause ILD such as antimicrobial&#xD;
             agents (Sulphonamide), cardiovascular agents (amiodarone) and Bromocriptine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Salwa omar</last_name>
    <phone>01206889948</phone>
    <email>salwa8774@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rania Mohamed</last_name>
    <phone>01206620088</phone>
    <email>drraniami@gmail.com</email>
  </overall_contact_backup>
  <link>
    <url>https://doi.org/10.21203/rs.3.rs-587880/v1</url>
    <description>Soluble Programmed Death Molecule 1 (sPD-1) As Predictor of Interstitial Lung Disease in Rheumatoid Arthritis</description>
  </link>
  <link>
    <url>https://doi.org/10.1016/j.jfma.2020.04.004</url>
    <description>The PD-1/PD-L pathway in rheumatic diseases</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1016/j.ejr.2014.12.002</url>
    <description>Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Salwa Omar Mohammed</investigator_full_name>
    <investigator_title>Resident doctor in Rhematology and rehabilitation department</investigator_title>
  </responsible_party>
  <keyword>Interstitial lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

